KalVista Pharmaceuticals, Inc. Update: The Company Has Been Acquired

If you have been following KalVista Pharmaceuticals, there is major news. The company is no longer an independent, publicly traded business. Here is what happened and what it means for you.

1. What happened?

The Italian pharmaceutical company Chiesi Group has officially acquired KalVista.

Chiesi purchased approximately 77.8% of KalVista’s shares through a tender offer, allowing them to complete a "short-form merger" under Delaware law. The merger officially closed on June 11, 2026, making KalVista a wholly owned subsidiary of Chiesi.

2. What does this mean for the stock?

The ticker symbol KALV is no longer active on the Nasdaq Global Select Market.

• The Payout: Former shareholders are entitled to $27.00 per share in cash, minus any applicable taxes.
• Trading: Because Chiesi now owns the company, KalVista shares no longer trade on any public exchange. You cannot buy or sell this stock.
• Options and RSUs: Employee stock options and restricted stock units (RSUs) were canceled and converted into the right to receive $27.00 per share, subject to specific vesting rules and tax withholdings.

3. Why did this happen?

KalVista’s primary value was its development of small-molecule protease inhibitors, specifically EKTERLY® (sebetralstat), an oral, on-demand treatment for hereditary angioedema (HAE).

By joining Chiesi, KalVista gains the global infrastructure and regulatory experience of a larger, established pharmaceutical company. This move is intended to accelerate the international launch of EKTERLY and provide the resources needed for ongoing clinical trials.

4. Who is affected?

• Investors: If you held shares in a brokerage account, your broker will automatically process the conversion of your shares into the $27.00 per share cash payment. You do not need to take any action to initiate this.
• Convertible Note Holders: The merger triggered a "Fundamental Change" for the 3.250% Convertible Senior Notes due 2029. Noteholders have the right to convert their notes into $1,606.28 in cash for every $1,000 of principal.
• Patients: The acquisition is expected to stabilize and expand the supply of EKTERLY, as Chiesi’s focus on rare diseases aligns with KalVista’s existing medical pipeline.

5. The Bottom Line

KalVista is no longer a public company. For retail investors, this investment has concluded. You will no longer receive quarterly earnings reports or SEC filings from KalVista.

What you should do now:

• Check your statements: Keep an eye on your brokerage account for the cash deposit.
• Update your watchlist: Since the stock is no longer trading, you can remove KALV from your portfolio trackers.
• Consult your broker: If you do not see your payment within a reasonable timeframe, contact your brokerage firm directly, as they handle the distribution of funds.

Disclaimer: I am an AI, not a financial advisor. This summary is for informational purposes only and is not professional investment advice. Please check with your brokerage regarding the specific timing and tax implications of your cash payout.